Table 1.
Baseline and demographic characteristics
| Parameter | Cohort 1: Platinum resistant, BRCA-wildtype with ≥3 prior lines of therapy N=53 | Cohort 2: Platinum resistant, BRCA-wildtype with <3 prior lines of therapy N=46 | Cohort 3: Platinum resistant, BRCA-mutated with prior PARP inhibitor therapy N=41 | Cohort 4: Platinum refractory with any number of prior lines of therapy N=29 | All cohorts N=169 |
|---|---|---|---|---|---|
| Age, mean (SD) | 61.3 (9.4) | 62.3 (9.4) | 59.5 (8.6) | 59.0 (13.4) | 60.8 (10.0) |
| Race, n (%) | |||||
| Asian | 6 (11.3) | 8 (17.4) | 4 (9.8) | 3 (10.3) | 21 (12.4) |
| African American | 0 (0.0) | 1 (2.2) | 0 (0.0) | 1 (3.4) | 2 (1.2) |
| Native Hawaiian or Pacific Islander | 1 (1.9) | 1 (2.2) | 0 (0.0) | 0 (0.0) | 2 (1.2) |
| White | 46 (86.8) | 36 (78.3) | 37 (90.2) | 25 (86.2) | 144 (85.2) |
| Initial pathological diagnosis*, n (%) | |||||
| Fallopian tube cancer | 4 (7.5) | 3 (6.5) | 1 (2.4) | 3 (10.3) | 11 (6.5) |
| Ovarian cancer | 43 (81.1) | 37 (80.4) | 37(90.2) | 22 (75.9) | 139 (82.2) |
| Primary peritoneal carcinoma | 6 (11.3) | 6 (13.0) | 3 (7.3) | 4 (13.8) | 19 (11.2) |
| Median time since primary diagnosis*, days(min-max)a Prior therapies | 1554 (506–4649) | 526 (247–2580) | 1803 (780–4572) | 446 (103–3648) | 1052 (103–4649) |
| Surgery | 51 (96.2) | 44 (95.7) | 41 (100.0) | 26 (89.7) | 162 (95.9) |
| Radiotherapy | 5 (9.4) | 1 (2.2) | 6 (14.6) | 2 (6.9) | 14 (8.3) |
| Systemic therapy | 53 (100.0) | 46 (100.0) | 41 (100.0) | 29 (100.0) | 169 (100.0) |
| Median prior systemic regimens | 4.0 (3.0,5.0) | 2.0 (1.0,2.0) | 5.0 (4.0,6.0) | 2.0 (1.0,3.0) | 3.0 (2.0,5.0) |
*
The total ‘N’ varied (N=138); Cohort 1 n=41; Cohort 2 n=39; Cohort 3 n=32; Cohort 4 n=26.
a
Duration of disease is the time from date of initial pathological diagnosis to date of first exposure to treatment
Abbreviation: BRCA, breast cancer gene; ECOG, Eastern Cooperative Oncology Group; SD, Stable disease.